Don't Miss Out

Subscribe to OCA's News & Alerts.

What You Don’t Know Could Hurt You: Novavax’s ‘Loud-and-Clear’ Nanoparticle Adjuvant

Advisors to the Centers for Disease Control and Prevention on Tuesday unanimously recommended Novavax’s COVID-19 vaccine, claiming the unvaxxed are the product’s “primary target population."

In recent months, COVID-19 vaccination in the U.S. has “slowed to a crawl” as an increasingly distrustful public says “no thanks” to primary shots and boosters.

Still, U.S. public health agencies continue to authorize, approve and recommend COVID-19 vaccines — even for infants.

On Tuesday, advisors to the Centers for Disease Control and Prevention (CDC) — perhaps believing they can reverse the slowdown in “vaccine uptake” and without admitting to the ravages caused by the Pfizer/BioNTech, Moderna and Johnson & Johnson (J&J) shots — unanimously recommended the “Novavax COVID-19 Vaccine, Adjuvanted.”

The U.S. Food and Drug Administration (FDA) last week granted Novavax Emergency Use Authorization (EUA) for its COVID-19 vaccine, for adults age 18 and up.

Back in 2020, Operation Warp Speed awarded Novavax — another company that like Moderna, never brought a product to market before COVID-19 — a secret contract worth $1.6 billion (now being reported as $1.8 billion).